Cumberland Pharmaceuticals Inc.

Good afternoon, and welcome to the Cumberland Pharmaceuticals' fourth quarter 2024 financial report and company update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I would now like to turn it over to Molly Agus, Account Supervisor of the Dalton Agency, who handles Cumberland's communications. Molly, please proceed.

Hello, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its fourth quarter and annual financial results for the year ending December 31st, 2024. The release also provided an operational update, including key recent developments. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. Management will share an overview of those financial results during today's call. They'll also provide an overall company update, including a discussion of Cumberland's brands, pipeline, and partners. Participating in today's call are A.J. Kazemi, Cumberland's Chief Executive Officer, Todd Anthony, Vice President, Organizational Development, and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, public health epidemics, international conflicts, trade restrictions, and others that are beyond the company's control. Those issues are described under the caption risk factors in Cumberland's Form 10-K and any additional updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations, so information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future development. During today's call, there will be references to several of Cumberland's marketed brands. Full prescribing and safety information for each brand is included on the individual product websites. And you can find links to those sites on the corporate website at www.cumberlandpharma.com. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the financial tables of the earnings release, which was issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point we will be happy to answer them. Management's also prepared to hold a follow-up conversation after the call, if you prefer. So, with that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J. Kazemi.

Thank you, Molly, and good afternoon, everyone. We do appreciate you joining us today as we share financial results and provide an update on our progress here at Cumberland. As Molly mentioned, during the call, we'll review both fourth quarter and full year 2024 financial performance. And we'll also share a company update, which will include some highlights from a successful 2024, as well as some key recent developments. So let's begin. For those that have been following Cumberland over the years, recall our business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We've also built an internal development capability, which enables us to develop and register new medicines, establishing a long-term pipeline for our business. And that pipeline is enhanced through our Cumberland Emerging Technologies, or CET Division, which is a joint initiative mainly with Vanderbilt University and their prominent academic research center. Well, despite various headwinds over the past several years, we've not deviated from these strategies. In fact, we continue to move forward by acquiring new brands, expanding our sales organization, advancing our development pipeline, securing a series of FDA approvals, and broadening our reach through a series of international partnerships. And as you'll see in our comments today, that steadfast approach is gaining traction, and it's now being recognized by the investment community for the dramatic growth in our share valuation. We recently reported significant progress on several fronts. We announced positive phase two study data, evaluating our iFitraBand product candidate in patients with Duchenne muscular dystrophy. That breakthrough had a dramatic impact on our share price and trading volumes. And I believe it's the first time we're seeing investors beginning to recognize the value of our development capabilities and pipeline. And we learned that our potent antibiotic, Fibative, received approval by the regulatory authorities in China, the world's second largest pharmaceutical market. And that milestone adds to our growing international business as we also began shipping Vibative to Saudi Arabia and completed the needed product training to launch the product there. Before discussing these achievements in more detail, I'd like to take a few minutes and share a number of key developments during 2024 that enabled us to make significant progress in advancing our newly refined mission of working together to provide unique products that improve the quality of patient care. During 2024, we announced the publication of new real-world outcomes research involving 150,000 patients, which compared our ibuprofen injection product, Caldolor, to its key competitor, Ketorolac. The results provided compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions and can also help provide cost savings through improved healthcare system utilization. Meanwhile, we reported the FDA approval of a supplemental new drug application for acetidote are IV treatment for preventing or lessening the liver injury that occurs after ingestion of potentially toxic quantities of acetaminophen. The new, streamlined approach reduces the frequency of medication errors and potentially serious non-allergic anaphylactoid reactions without compromising the effectiveness of acetidote. By simplifying the product's dosing regimen, healthcare providers can administer this life-saving treatment more efficiently, potentially improving patient outcomes. And thirdly, we received both orphan drug designation and rare pediatric disease designation from the FDA for the use of our FitrBand product in treating Duchenne muscular dystrophy heart disease, reflecting its potential significance in helping with this devastating condition. Turning to the Q4 financial results, I'm pleased to report our portfolio of FDA-approved brands delivered strong net revenues of $10.4 million, which represented an 11.6% increase over the prior year period. So with that overview, I'd now like to turn it over to Todd Anthony, Cumberland's Vice President, Organizational Development, to further discuss both our brands and our organization. Todd? Well, thank you, AJ.